Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock

  • Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ:ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for ARQT. 
  • The most important catalyst is the potential approval of roflumilast cream in plaque psoriasis around July 29, 2022, transforming Arcutis from a developmental- to a commercial-stage company. 
  • Mizuho believes the three ongoing Phase 3 clinical programs remain underappreciated by investors. 
  • Related: Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast.
  • The topline data for seborrheic dermatitis is expected in mid-2022. The analyst expects positive data given the similar trial size and patient enrollment number to the highly positive Phase 2 trial. 
  • The analyst expects a positive readout from Phase 3 in scalp psoriasis for scalp psoriasis. 
  • The likelihood of success of the Phase 3 studies in atopic dermatitis is questionable as Phase 2 missed the EASI primary endpoint. The Phase 2 trial was also underpowered. 
  • Price Action: Yesterday's shares fell from $22.33 to $19.60. Today the stock is trading 0.26% higher at $19.65 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.